CoChat

Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian Carcinoma

Open access
Han, Liz Y., Landen, Charles N., Trevino, Jose G., Halder, Jyotsnabaran, Lin, Yvonne G., Kamat, Aparna A., Kim, Tae-Jin, Merritt, William M., Coleman, Robert L., Gershenson, David M., Shakespeare, William C., Wang, Yihan, Sundaramoorth, Raji, Metcalf, Chester A., Dalgarno, David C., Sawyer, Tomi K., Gallick, Gary E., Sood, Anil K. · 2006 · Cancer Research
Cited by 94

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Src, a nonreceptor tyrosine kinase, is a key mediator for multiple signaling pathways that regulate critical cellular functions and is often aberrantly activated in a number of solid tumors, including ovarian carcinoma. The purpose of this study was to determine the role of activated Src inhibition on tumor growth in an orthotopic murine model of ovarian carcinoma. In vitro studies on HeyA8 and SKOV3ip1 cell lines revealed that Src inhibition by the Src-selective inhibitor, AP23846, occurred within 1 hour and responded in a dose-dependent manner. Furthermore, Src inhibition enhanced the cytotoxicity of docetaxel in both chemosensitive and chemoresistant ovarian cancer cell lines, HeyA8 and HeyA8-MDR, respectively. In vivo, Src inhibition by AP23994, an orally bioavailable analogue of AP23846, significantly decreased tumor burden in HeyA8 (P = 0.02), SKOV3ip1 (P = 0.01), as well as HeyA8-MDR (P < 0.03) relative to the untreated controls. However, the greatest effect on tumor reduction was observed in combination therapy with docetaxel (P < 0.001, P = 0.002, and P = 0.01, for the above models, respectively). Proliferating cell nuclear antigen staining showed that Src inhibition alone (P = 0.02) and in combination with docetaxel (P = 0.007) significantly reduced tumor proliferation. In addition, Src inhibition alone and in combination with docetaxel significantly down-regulated tumoral production of vascular endothelial growth factor and interleukin 8, whereas combination therapy decreased the microvessel density (P = 0.02) and significantly affected vascular permeability (P < 0.05). In summary, Src inhibition with AP23994 has potent antiangiogenic effects and significantly reduces tumor burden in preclinical ovarian cancer models. Thus, Src inhibition may be an attractive therapeutic approach for patients with ovarian carcinoma. (Cancer Res 2006; 66(17): 8633-9)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-06-1410

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 94

Metadata

Authors
Han, L. Y., Landen, C. N., Trevino, J. G., Halder, J., Lin, Y. G., Kamat, A. A., Kim, T.-J., Merritt, W. M., Coleman, R. L., Gershenson, D. M., Shakespeare, W. C., Wang, Y., Sundaramoorth, R., Metcalf, C. A., Dalgarno, D. C., Sawyer, T. K., Gallick, G. E., & Sood, A. K.
Venue
Cancer Research
Published
2006-09-01
Volume
66
Issue
17
Pages
8633-8639
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2170726369
Cited by
94
References
6
FWCI
6.87
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian Carcinoma. https://app.cochat.ai/papers/10.1158/0008-5472.can-06-1410
The paper
Han, L. Y., Landen, C. N., Trevino, J. G., Halder, J., Lin, Y. G., Kamat, A. A., Kim, T.-J., Merritt, W. M., Coleman, R. L., Gershenson, D. M., Shakespeare, W. C., Wang, Y., Sundaramoorth, R., Metcalf, C. A., Dalgarno, D. C., Sawyer, T. K., Gallick, G. E., & Sood, A. K. (2006). Antiangiogenic and Antitumor Effects of Src Inhibition in Ovarian Carcinoma. Cancer Research. https://doi.org/10.1158/0008-5472.can-06-1410

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.